The overall survival rate among patients in the bicalutamide group at twelve year showed twenty-one of the patients receiving the treatment had died from prostate cancer, versus the forty-six patients in the placebo group. In 2010, the study showed that treatment with bicalutamide led to a reduction in both biochemical recurrence and the development of metastases Due to the slow process of prostate cancer, researchers wanted a longer-term follow-up to determine whether some participants could be considered cured of their disease. In this article it shows the importance of randomized clinical trials with very long follow-up, that lead to amazing results in the fight of recurrent prostate
The overall survival rate among patients in the bicalutamide group at twelve year showed twenty-one of the patients receiving the treatment had died from prostate cancer, versus the forty-six patients in the placebo group. In 2010, the study showed that treatment with bicalutamide led to a reduction in both biochemical recurrence and the development of metastases Due to the slow process of prostate cancer, researchers wanted a longer-term follow-up to determine whether some participants could be considered cured of their disease. In this article it shows the importance of randomized clinical trials with very long follow-up, that lead to amazing results in the fight of recurrent prostate